Clinical Trials Directory

Trials / Unknown

UnknownNCT02758977

Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) vs. Two-Stage Hepatectomy (TSH) for Marginally Resectable Colorectal Liver Metastases (CRLM)

Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) vs. Conventional Two-Stage Hepatectomy (TSH) for Surgical Treatment of Marginally Resectable Colorectal Liver Metastases (CRLM) - A Multicentric, Randomized Controlled Trial

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
214 (estimated)
Sponsor
University of Zurich · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Surgical resection has offered the best option for prolonged survival in patients with colorectal liver metastases. Limiting factor for major liver resections is the size of the future liver remnant (FLR). In case of normal liver function, 30% of the total liver volume is considered to be sufficient to maintain adequate liver function after resection. In an attempt to further increase "resectability" criteria for patients with too small FLR surgical and interventional maneuvers such as portal vein embolization and portal vein ligation in two-stage hepatectomies have been implemented, but they need an interval of 4-8 weeks to achieve sufficient hypertrophy. In order to obtain adequate but rapid parenchymal hypertrophy a new surgical two-step technique, ALPPS, was introduced for oncological patients requiring extended hepatic resection with limited functional reserve. Both procedures can be performed with acceptable morbidity and mortality. The investigators conclude that it is time to perform a randomized study comparing the two surgical approaches in regard to oncological outcome.

Conditions

Interventions

TypeNameDescription
PROCEDUREALPPSFor detailed information please refer to description of experimental arm
PROCEDURETWO STAGE HEPATECTOMYFor detailed information please refer to description of active comparator arm

Timeline

Start date
2016-05-01
Primary completion
2019-04-01
First posted
2016-05-03
Last updated
2016-05-03

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT02758977. Inclusion in this directory is not an endorsement.